Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, drawn from the whole corpus: 11 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No drug alters the disease course; RAS-pathway inhibitors, GM-CSF antibodies and venetoclax combinations are in early trials.
Transformation to AML in a substantial minority; sequential mutation tracking to intervene earlier is being studied.
Transplant is curative but most patients are old; reduced-intensity conditioning and better donor availability widen access.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Trials usually lump CMML with MDS or exclude it; dedicated CMML cohorts and registries (such as the European Hematology Association consortium) are the response.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
Monocyte threshold lowered to 0.5 x 10^9/L with molecular support; dysplastic vs proliferative subtypes formalised.
MDS/CMML
MDS and CMML
A milestone in how this cancer is treated.
Such and colleagues; CPSS-Mol adds mutations in 2016.